

575 North Patterson Avenue, Suite 550
Winston-Salem, NC 27101
p +1.336.716.8508
f +1.336.777.3260
Innovation@wakehealth.edu
WakeForestInnovations.com

October 23, 2014

The Blazeman Foundation for ALS PMB 121
18 Maple Avenue
Barrington, Rhode Island 02806

Dear Mr. and Mrs. Blais,

I am pleased to confirm our support of both Dr. Milligan's novel project using recombinant heat-shock protein 70 as a potential therapeutic for ALS and the continued partnership with the Blazeman Foundation to complete the pre-clinical studies required to bring this technology into the clinic.

Alongside Dr. Milligan's lab working to validate the standard operating procedure for protein production and confirming the previous results in the mouse model of ALS, I am eager to provide advice regarding the resources and facilities required for GMP production of the protein that will be required for clinical trials. I am also ready to provide advice in drug development and industry partnerships.

It is critical that we determine whether funding can be made available to carry this project through to completion, i.e., registration with the FDA for product use. For this, I will keep this project in mind as I meet with potential investors and will be pleased to discuss it with a local investment group focusing on orphan diseases. Going into and through clinical trials to product registration takes several years and will be costly. However, as there is no effective treatment for this devastating disease, I admire Dr. Milligan's efforts and the Blazeman Foundation's commitment to this project, and will provide all the assistance needed to bring the project to a successful conclusion.

Sincerely,

Eric Tomlinson, D.Sc., Ph.D.

Chief Innovation Officer, Wake Forest Baptist Medical Center President, Wake Forest Innovation Quarter Professor of Physiology & Pharmacology, Wake Forest School of Medicine

etomlins@wakehealth.edu

+1.336.716.4903